Mitochondrial-derived peptide mots3 regulates metabolism and cell survival

Abstract

MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.

We claim: 
     
         1 . An isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1. 
     
     
         2 . The polypeptide of  claim 1 , comprising 80% sequence identity to SEQ ID NO:1. 
     
     
         3 . The polypeptide of  claim 1 , comprising 90% sequence identity to SEQ ID NO:1. 
     
     
         4 . The polypeptide of  claim 1 , comprising the sequence of SEQ ID NO:1. 
     
     
         5 . An isolated antibody that specifically binds to the polypeptide comprising 70% sequence identity to SEQ ID NO: 1. 
     
     
         6 . The antibody of  claim 5 , wherein the antibody is a monoclonal antibody. 
     
     
         7 . A pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1. 
     
     
         8 . The composition of  claim 7 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1. 
     
     
         9 . The composition of  claim 7 , wherein the polypeptide comprises the sequence of SEQ ID NO:1. 
     
     
         10 . A method of treating diabetes, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1. 
     
     
         11 . The method of  claim 10 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1. 
     
     
         12 . The method of  claim 10 , wherein the polypeptide comprises the sequence of SEQ ID NO:1. 
     
     
         13 . The method of  claim 10 , wherein the diabetes is type I diabetes. 
     
     
         14 . The method of  claim 10 , wherein the diabetes is type II diabetes. 
     
     
         15 . The method of  claim 10 , wherein the subject is a human. 
     
     
         16 . A method of treating obesity and/or fatty liver, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1. 
     
     
         17 . The method of  claim 16 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1. 
     
     
         18 . The method of  claim 16 , wherein the polypeptide comprises the sequence of SEQ ID NO:1. 
     
     
         19 . The method of  claim 16 , wherein the subject is a human. 
     
     
         20 . A method of treating cancer, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1. 
     
     
         21 . The method of  claim 20 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1. 
     
     
         22 . The method of  claim 20 , wherein the polypeptide comprises the sequence of SEQ ID NO:1. 
     
     
         23 . The method of  claim 20 , wherein the subject is a human. 
     
     
         24 . The method of  claim 20 , wherein the cancer is a cancer selected from a group consisting of breast cancer, brain cancer, colon cancer, melanoma, leukemia (e.g., AML), lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, lung cancer, and gastric cancer.